Developer of cancer immunotherapies that focuses on streamlined biotechnology development, including high throughput antigen-specific TCR (T cell antigen receptor) cloning, industry scale virus production, T cell genetic engineering, and immune cell manufacturing.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC (Series B) | 02-Apr-2019 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A) | 03-Dec-2018 | Completed | Generating Revenue | |||
1. Seed Round | 03-Aug-2016 | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Qijing Li Ph.D | Founder & Chief Scientific Officer |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Emerging Technology Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Share Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Fang Fund Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Jiadao Valley Investment | Venture Capital | Minority | 000 0000 | 000000 0 | |
In Capital | Asset Manager | Minority | 000 0000 | 000000 0 |